ESMO China Voice | Professor Xiaojia Wang: Aromatase Inhibitor Treatment for mBC Progression? Anlotinib Combined with Fulvestrant Offers New Hope

ESMO China Voice | Professor Xiaojia Wang: Aromatase Inhibitor Treatment for mBC Progression? Anlotinib Combined with Fulvestrant Offers New Hope

Hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer accounts for over 70% of all breast cancers[1]. The use of CDK4/6 inhibitors has brought about a breakthrough in the survival of these late-stage patients. However, some recurrent metastatic patients may develop endocrine resistance, reducing the efficacy of treatment. The European Society for Medical Oncology (ESMO) 2023 Annual Congress, held in Madrid, Spain, on October 20, 2023, featured Professor Xiaojia Wang's poster presentation on the combination of anlotinib and fulvestrant (452P), providing new hope for these patients. Oncology Frontier invited Professor Xiaojia Wang from Zhejiang Cancer Hospital to share insights.
Alexander Mundinger：

Alexander Mundinger：

Cost-Effectiveness of Breast Cancer Screening Editor's Note: The 2023 China Congress of Integrative Oncology (2023 CCHIO) will be held in Tianjin from November 16th to 19th, 2023. Dr. Alexander Mundinger,…

Prof. Zhong-Qiu Lin: Creating a Protective Umbrella for the Cancer Prevention and Treatment of Chinese Women

Protecting the health of Chinese women and providing a robust defense against gynecological cancer requires the integration of more resources and efforts in the field of gynecological cancer prevention and treatment. On the eve of the "2023 Chinese Congress on Holistic Integrative Oncology (2023 CCHIO)," Oncology Frontier interviewed Prof. Zhong-Qiu Lin, Chairman of the Cervical Cancer Professional Committee of the China Anti-Cancer Association and Sun Yat-sen Memorial Hospital, to discuss the current status of gynecological cancer prevention and treatment in China, recent advances in maintenance therapy for advanced-stage cases, and the developmental vision of the Cervical Cancer Professional Committee of the China Anti-Cancer Association.